言語を選択
Integrin alpha V beta 3
Integrin alpha V beta 3 詳細
| 英語名 | Integrin alpha-V/beta-3 | 市販薬剤の数 | 0 |
| 治験薬の数 | 29 | ターゲットの別称 | Integrin alphaVbeta3 |
| 研究＆開発段階 | NDA/BLA | ||
| 英語名 | Integrin alpha-V/beta-3 |
| ターゲットの別称 | Integrin alphaVbeta3 |
| 市販薬剤の数 | 0 |
| 治験薬の数 | 29 |
| 研究＆開発段階 | NDA/BLA |
Integrin alpha V beta 3 製品リスト
- 属性
Protein (7)
- 製品ライブラリ
オンライン (7)
- 種
Human (2)Rat (1)Cynomolgus (2)Mouse (2)
- タグ
His Tag (4)His Tag & Avi Tag (3)
- マーカー
Unconjugated (4)Biotin-labeled (3)
総数量7
- 1
Integrin alpha V beta 3バックグランド
Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Also, Integrin alpha-V/beta-3 acts as a receptor for herpes virus 8/HHV-8, coxsackievirus A9, Hantaan virus, cytomegalovirus/HHV-5, human metapneumovirus, human parechovirus 1 and west nile virus. Furthermore, in case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
Integrin alpha V beta 3分子の別称
Integrin alpha V beta 3,ITGAV&ITGB3
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Alfatide[18F] | 18F-AlF-NOTA-PRGD2; 18F-alfatide; alfatide II; AlF-NOTA-PRGD2-[18F] | Phase 3 Clinical | Jiangsu Smk Pharmaceutical Co Ltd, Taizhou Kairui Pharmaceutical Technology Co Ltd | Breast Neoplasms; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Contrast agents; Head and Neck Neoplasms; Lung Neoplasms; Lymphoma; Neoplasms; Soft Tissue Neoplasms | 詳細 |
| 18F-LNC1016 | 18F-LNC-1016; 18F-LNC1016 | Phase 3 Clinical | Yantai Lannacheng Biotechnology Co Ltd | Lung Neoplasms | 詳細 |
| 18F-LNC1007 | 18F-LNC1007; 18F-FAPI-RGD | Phase 3 Clinical | Yantai Lannacheng Biotechnology Co Ltd | Carcinoma, Renal Cell; Diagnostic agents; Neoplasms; Solid tumours | 詳細 |
| IDL-2965 | IDL-2965 | Phase 2 Clinical | Indalo Therapeutics Inc | Idiopathic Pulmonary Fibrosis; Metabolic Dysfunction-Associated Steatotic Liver Disease | 詳細 |
| Nesvategrast | SF-0166; OTT-166(OcuTerra Therapeutics) | Phase 2 Clinical | OcuTerra Therapeutics Inc, Scifluor Life Sciences Inc | Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration | 詳細 |
| 68Ga-FAP-RGD | 68Ga-FAP-RGD | Phase 2 Clinical | First Affiliated Hospital Of Fujian Medical University | Neoplasms | 詳細 |
| 68Ga-HX01 | 68Ga-HX01; 68GaHX01 | Phase 2 Clinical | Hexin (Suzhou) Pharmaceutical Technology Co Ltd | Contrast agents; Neoplasms; Sarcoma; Solid tumours | 詳細 |
| ProAgio | Phase 2 Clinical | National Cancer Institute | Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Pancreatic Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | 詳細 | |
| Ga-68 NODAGA-RGD | Theranost 68Ga-RGD; [68Ga]Theranost | Phase 1 Clinical | Advanced Imaging Projects, National Cancer Institute, Zentralklinik Bad Berka | Lung Neoplasms; Neovascularization, Pathologic | 詳細 |
| Risuteganib | ALG-1001; AM011; AM-011(Allegro Ophthalmics) | Phase 1 Clinical | Allegro Ophthalmics Llc | Diabetic macular oedema; Diabetic Retinopathy; Geographic Atrophy; Macular Degeneration | 詳細 |
| 68Ga-NOTA-BBN-RGD | 68Ga-NOTA-BBN-RGD | Phase 1 Clinical | Peking Union Medical College Hospital | Breast Neoplasms; Prostatic Neoplasms | 詳細 |
| BGC-0222 | BGC0222; BGC-0222 | Phase 1 Clinical | Brightgene Bio-Medical Technology Co Ltd, Gaorui Yaoye (Beijing) Technologies Co Ltd | Solid tumours | 詳細 |
| Antiangiotide | HM-3; IIM-3 | Phase 1 Clinical | China Pharmaceutical University, Inner Mongolia Tianqi Pharmaceutical Group Co Ltd | Carcinoma, Non-Small-Cell Lung; Liver Neoplasms; Lung Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| 68Ga-NOTA-3PTATE-RGD | 68Ga-NOTA-3P-TATE-RGD; 68Ga-NOTA-3PTATE-RGD | Phase 1 Clinical | Peking Union Medical College Hospital | Carcinoma, Neuroendocrine; Lung Neoplasms; Meningioma; Neuroendocrine Tumors | 詳細 |
| 177Lu-FF-10158 | 177Lu-FF-10158 | Phase 1 Clinical | Fujifilm Holdings Corp | Glioblastoma | 詳細 |
| Transferrin | OCU-200 | Phase 1 Clinical | Ocugen Inc | Diabetic macular oedema; Diabetic Retinopathy; Wet Macular Degeneration | 詳細 |
| VIP-236 | VIP-236 | Phase 1 Clinical | Bayer AG | Neoplasms; Solid tumours | 詳細 |
| 177Lu-HX02 | 177Lu-HX02; 177Lu-HX-02 | Phase 1 Clinical | Hexin (Suzhou) Pharmaceutical Technology Co Ltd | Neoplasms; Solid tumours | 詳細 |
| 177Lu-FAPI-RGD | 177Lu-FAPI-RGD; [177Lu]-FAPI-RGD | Phase 1 Clinical | Peking Union Medical College Hospital | Neoplasms | 詳細 |
| 177Lu-TATE-RGD | 177Lu-TATE-RGD | Phase 1 Clinical | Peking Union Medical College Hospital | Neoplasms | 詳細 |
| 177Lu-LNC1009 | 177Lu-LNC1009; 177Lu-LNC-1009 | Phase 1 Clinical | Yantai Lannacheng Biotechnology Co Ltd | Solid tumours | 詳細 |
| 177Lu-LNC1008 | 177Lu-LNC1008 | Phase 1 Clinical | Yantai Lannacheng Biotechnology Co Ltd | Solid tumours | 詳細 |
| 68Ga-LNC-1007 | 68Ga-FAPI-RGD; 68Ga-LNC-1007 | Phase 1 Clinical | Yantai Lannacheng Biotechnology Co Ltd | Carcinoma, Renal Cell; Neoplasms | 詳細 |
| NP-011 | NP-011 | Phase 1 Clinical | Nexell Therapeutics Inc | Myocardial Infarction | 詳細 |
| (68)Ga-RGD | Phase 1 Clinical | Peking Union Medical College Hospital | Keloid | 詳細 | |
| fb-PMT | NP-100; NP-751 | Phase 1 Clinical | NanoPharmaceuticals LLC | Glioma | 詳細 |
| 177Lu-AB-3PRGD2 | 177Lu-AB-3PRGD2 | Phase 1 Clinical | Peking Union Medical College Hospital | Neoplasms; Solid tumours | 詳細 |
| Pagantangentide | Phase 1 Clinical | China Pharmaceutical University, Jiangsu Aotexin Biomedical Technology Co Ltd, Nanjing Anji Biological Technology Co Ltd | Arthritis, Rheumatoid; Rheumatic Diseases | 詳細 | |
| Lutetium-177 EBRGD (Molecular Targeting Technologies) | 177Lu-EBRGD; Lu-177 EBRGD; 177Lu-EB-RGD | Clinical | National Institute Of Biomedical Innovation | Carcinoma, Non-Small-Cell Lung; Glioblastoma | 詳細 |
- 詳細
- 製品リスト
- 治験薬に関する情報
共有：
メッセージ
お問い合わせ
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
メールアドレス
order.jp@acrobiosystems.com
アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8